 |
SV Life Sciences Fund IISVLSF II closed in 1999 with total commitments of $280 million (plus $30 million of co-investments committed by partners and individuals affiliated with SVLS). As at 31 March 2010, the fund had invested $328 million (including re-investment) in 36 portfolio companies. To go to individual portfolio companies websites please click on company logo. SV Life Sciences Fund II (SVLSFII)
Achillion: US
First investment: 2000 - Start Up Achillion is based in New Haven, CT, Achillion is focused on the discovery, development and commercialization of innovative small molecule therapeutics for the treatment and/or prevention of serious infections associated with drug resistant viruses or bacteria. 
AcuFocus: US
First investment: 2001 - Seed AcuFocus is based in Irvine, CA, AcuFocus is developing an implantable corneal in-lay for correction of presbyopia. 
Aderis Pharmaceuticals: US - Exited
First investment: 2001 - Expansion Aderis Pharmaceuticals was a Cardiovascular, renal and neurological disease focused therapeutics focused upon making a significant difference to people living with cardiovascular, renal and neurological diseases. 
Affibody: Sweden - Exited
First investment: 2001 - Early Stage Affibody is a biotech company that uses unique affinity ligands to develop products for molecular imaging, targeted therapy and biotechnology applications. The lead product is a Her2 affibody for clinical imaging in breast cancer, and its pipeline includes other oncology imaging affibodies. In addition, affibodies are sold as research reagents and for use in protein separations. 
AllianceCare: US
First investment: 2000 - Start Up AllianceCare is based in Boynton Beach, FL, a senior healthcare provider of nursing and physician housecall services, rehabilitation therapy and home health services through 20 branch offices and over 150 senior communities located in Florida, Texas and Ohio. The “At Home” merger also added private duty home care services in MA, IL, DC, MD, GA, and PA. 
Argonaut Technologies: US - Exited
First investment: 1999 - Expansion Argonaut developed a chemistry instrumentation for accelerated synthesis of novel organic molecules. Bought by Biotage after our exit. 
Auxilium Pharmaceuticals: US - Exited
First investment: 2001 - Early Stage Auxilium developed a male hormone replacement therapy. 
Cadent Technologies: US
First investment: 2000 - Early Stage Cadent is based in Carlstadt, NJ and has developed proprietary computer aided design (CAD/CAM) applications for the orthodontist and dental markets, which are deployed via a web-based service model on a pay per use basis. 
Cardiac Support Systems: US - Exited
First investment: 2000 - Seed Cardiac Support Systems was an innovation factory company. 
CardioFocus: US
First investment: 1999 - Early Stage CardioFocus is based in Marlborough, MA and has developed a catheter based approach using laser energy with visualization focused on atrial fibrillation. 
Celldex/Lorantis: UK - Exited
First investment SVLSF II: 2000 - Start Up First investment SVLSF III: 2003 - Early Stage Celldex merged with the quoted company Avant Immunotherapeutics (ticker:'AVAN') in March 2008. Celldex, formerly a wholly owned subsidiary of Medarex Inc., merged with Lorantis Ltd in 2005. Celldex pursues immunological approaches to the treatment of cancers, infectious disease and immunological disorders. 
Cellzome: Germany
First investment: 2001 - Start Up Cellzome is a drug discovery company building a R&D pipeline in chronic diseases by leveraging its unique drug proteomics engine. The business is based in Heidelberg, Germany and Cambridge, UK. 
Cerebral Vascular Applications: US - Exited
First investment: 2000 - Seed Cerebral Vascular Applications incubated by TIF) developed a set of minimally invasive tools for atrial appendage sealing for stroke prevention. Licensed to Epitek. Funded through the innovation factory 
Cognis: Luxembourg
First investment: 2001 - Buyout Cognis is a global supplier of specialty chemicals using renewable, bio-degradable,natural oils as the key raw material base. Customers include international manufacturers of cosmetics, vitamins and nutritional supplements and homecare products as well as a broad range of industrial customers. 
Confluent Surgical: US - Exited
First investment: 1999 - Early Stage Confluent Surgical was a biomaterials for adhesion prevention and vascular embolics. EasyChem: US - Exited First investment: 2000 - Seed EasyChem was a B2B chemical e-commerce electronic marketplace. 
eMed Technologies: US - Exited
First investment: 2000 - Expansion eMed Delivered medical images over the internet. Expand Sante: France - Exited First investment: 2000 - Seed Expand Sante was a French pharmaceutical contract sales organisation. 
Eyetech Pharmaceuticals: US - Exited
First investment: 2000 - Early Stage Eyetech was bought by OSI Pharmaceuticals after our exit. Opthalmolological drug development. 
IHG Holdings: US - Exited
First investment: 2001 - Buyout IHG was a preferred provider organization. (Formerly known as Interplan). 
Ingenium: Germany - Exited
First investment: 2000 - Early Stage Ingenium was a functional genomics and drug development company. 
Insulet: US - Exited
First investment SVLSF II: 2001 - Start Up Insulet based in Bedford, MA, Insulet is designing and developing products that provide superior treatment for people with diabetes. The Company’s first commercial product is a wireless 3-day insulin pump. 
KuDOS Pharmaceuticals: UK - Exited
First investment: 1999 - Start Up KuDOS was an oncology drug development company. 
LipoSonix: US - Exited
First investment SVLSF II: 2001 - Seed First investment SVLSF III: 2003 - Seed LipoSonix based in Bothell, WA, was developing a product to use non-invasive, high intensity focused ultrasound to ablate unwanted subcutaneous cells as a non-invasive alternative to liposuction for body sculpting. Funded through the innovation factory. 
Mdeverywhere: US - Exited
First investment: 2001 - Early Stage Mdeverywhere based in Hauppauge, NY with operations in New Dehli, India, is an outsourced physician billing company. 
Metris Therapeutics: UK - Exited
First investment SVLSF I: 1998 - Start Up First investment SVLSF II: 2000 - Start Up Metris is a women’s healthcare company that is developing drugs for the treatment of chronic gynecological and menstrual conditions. 
Orchid Chemicals and Pharmaceuticals: India - Exited
Private investment in Public Equity First investment: 1999 - Expansion Orchid manufactured bulk generic pharmaceuticals. 
Oxagen: UK
First investment: 2000 - Expansion Oxagen, based in Oxford, UK, is a biopharmaceutical company building a novel drug pipeline based on targets validated in man through its genetic platform. Oxagen’s work is focused in inflammatory and metabolic diseases. 
Phase Forward: US - Exited
First investment: 1999 - Expansion Phase Forward was a web-based information technology for clinical trials management. 
Physicians Dialysis: US - Exited
First investment: 2001 - Buyout Physicians Dialysis was a consolidator of renal dialysis centers (Purchased by DaVita). 
Quantum Dot: US - Exited
First investment: 2000 - Early Stage Quantum Dot developed nanocrystal biological reagents. 
Quick Study Radiology: US
First investment: 2000 - Start Up QSR based in St. Louis, MO, sells comprehensive digital imaging services to community hospitals and imaging centers. The company integrates, manages and supports clinical and data systems for customers with a focus on underserved small and secondary city locations. 
Solexa: UK - Exited
First investment: 2001 - Start Up Solexa used ultra high throughput DNA sequencing. 
Third Wave Technologies: US - Exited
First investment: 1999 - Expansion Third Wave developed products for analysing genetic variations. 
Trine Pharmaceuticals: US - Exited
First investment: 2001 - Expansion Trine, formerly Essential Therapeutics Inc., in-licenses, develops and plans to commercialize new classes of pharmaceutical products focused on renal, metabolic and GI clinical areas. 
Versicor: US - Exited
First investment: 1999 - Expansion Versicor was a drug development company for infectious diseases (Changed name to Vicurion Pharmaceuticals in 2003) 
| |
